China Traditional Chinese Medicine Holdings Co. Limited (CHIZF) Aktienanalyse
Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
China Traditional Chinese Medicine Holdings Co. Limited (CHIZF) ist im Healthcare-Sektor taetig, zuletzt notiert bei $ mit einer Marktkapitalisierung von 0. Bewertet mit 44/100 (vorsichtig) bei Wachstumspotenzial, finanzieller Gesundheit und Momentum.
Zuletzt analysiert: 16. März 2026China Traditional Chinese Medicine Holdings Co. Limited (CHIZF) Gesundheitswesen & Pipeline-Uebersicht
China Traditional Chinese Medicine Holdings Co. Limited, established in 1573, focuses on researching, developing, producing, and selling traditional Chinese medicine and pharmaceutical products. Operating primarily in the People's Republic of China, the company offers a diverse portfolio of TCM products, including granules, finished drugs, and decoction pieces, catering to hospitals and retail pharmacies.
Investmentthese
China Traditional Chinese Medicine Holdings Co. Limited presents a mixed investment profile. The company's long history and established presence in the Chinese TCM market provide a solid foundation. However, the company's negative profit margin of -1.7% and negative ROE of -1.4% raise concerns about profitability and efficiency. With a market capitalization of $1.38 billion and a debt-to-equity ratio of 15.38, the company appears financially stable, but the lack of free cash flow ($0.00B) is a concern. Growth catalysts include expanding its product line and increasing its market share within China. The beta of 0.74 suggests lower volatility compared to the broader market.
Basierend auf FMP-Finanzdaten und quantitativer Analyse
Wichtige Highlights
- Market capitalization of $1.38 billion, indicating a significant presence in the TCM market.
- Gross margin of 47.7%, reflecting a strong ability to manage production costs.
- Debt-to-equity ratio of 15.38, suggesting a conservative approach to financial leverage.
- Beta of 0.74, indicating lower volatility compared to the overall market.
- Founded in 1573, demonstrating a long-standing history and established brand in the TCM industry.
Wettbewerber & Vergleichsunternehmen
Staerken
- Long-standing history and established brand in the TCM market.
- Integrated operations, from herb cultivation to product distribution.
- Diverse product portfolio catering to various healthcare needs.
- Established distribution network across China.
Schwaechen
- Negative profit margin and return on equity.
- Lack of free cash flow.
- Reliance on the Chinese market.
- Potential quality control issues in TCM production.
Katalysatoren
- Ongoing: Expansion of product lines to include innovative TCM formulations.
- Ongoing: Geographic expansion within China to underserved regions.
- Ongoing: Increased investment in R&D to develop evidence-based TCM products.
- Ongoing: Strategic partnerships and acquisitions to expand capabilities.
- Ongoing: Leveraging e-commerce platforms to reach a wider customer base.
Risiken
- Potential: Stringent regulations and quality control requirements in the pharmaceutical industry.
- Potential: Competition from both domestic and international pharmaceutical companies.
- Potential: Fluctuations in the prices of raw materials.
- Potential: Adverse events related to TCM products.
- Ongoing: Negative profit margin and return on equity.
Wachstumschancen
- Expansion of TCM Product Lines: China Traditional Chinese Medicine Holdings Co. Limited can capitalize on the growing demand for TCM by expanding its product lines to include innovative formulations and specialized treatments. The global herbal medicine market is projected to reach $129.3 billion by 2028, presenting a significant opportunity for growth. This expansion can be achieved through internal research and development or strategic acquisitions of smaller TCM companies.
- Geographic Expansion within China: The company can further penetrate the Chinese market by expanding its distribution network to reach underserved regions and populations. The Chinese pharmaceutical market is the second-largest in the world, with significant growth potential in rural areas. This expansion can be facilitated through partnerships with local distributors and the establishment of new retail outlets.
- Increased Investment in R&D: Investing in research and development to create new TCM products and improve existing formulations can drive future growth. The company can focus on developing evidence-based TCM products that meet international quality standards. This will not only enhance the company's competitiveness but also open up opportunities for export to international markets.
- Strategic Partnerships and Acquisitions: Forming strategic partnerships with other pharmaceutical companies, research institutions, and healthcare providers can accelerate growth and expand the company's capabilities. Acquisitions of complementary businesses can provide access to new technologies, markets, and product lines. These partnerships can also facilitate the development of new TCM products and the improvement of existing formulations.
- Leveraging E-commerce Platforms: The company can leverage e-commerce platforms to reach a wider customer base and increase sales. Online sales of TCM products are growing rapidly in China, driven by the increasing popularity of online shopping. By establishing a strong online presence, the company can tap into this growing market and increase its revenue.
Chancen
- Expanding product lines to include innovative TCM formulations.
- Geographic expansion within China to underserved regions.
- Increased investment in R&D to develop evidence-based TCM products.
- Strategic partnerships and acquisitions to expand capabilities.
Risiken
- Stringent regulations and quality control requirements in the pharmaceutical industry.
- Competition from both domestic and international pharmaceutical companies.
- Fluctuations in the prices of raw materials.
- Potential for adverse events related to TCM products.
Wettbewerbsvorteile
- Established Brand: The company has a long-standing history and a well-recognized brand in the Chinese TCM market, dating back to 1573.
- Integrated Operations: The company's integrated operations, including cultivation of medicinal herbs, manufacturing, and distribution, provide a competitive advantage.
- Extensive Product Portfolio: The company offers a diverse portfolio of TCM products, catering to a wide range of healthcare needs.
- Distribution Network: The company has an established distribution network, reaching hospitals and retail pharmacies across China.
Ueber CHIZF
China Traditional Chinese Medicine Holdings Co. Limited, tracing its origins back to 1573, is an investment holding company deeply rooted in the research, development, production, and sale of traditional Chinese medicine (TCM) and pharmaceutical products. Headquartered in Wan Chai, Hong Kong, the company operates primarily within the People's Republic of China. Its comprehensive product portfolio includes granules, finished drugs, decoction pieces, and healthcare products, catering to a broad spectrum of healthcare needs. Beyond its core manufacturing activities, China Traditional Chinese Medicine Holdings Co. Limited is involved in the cultivation and management of Chinese medicinal herbs, ensuring a consistent supply of high-quality raw materials. The company also engages in the trading of pharmaceutical products, provision of TCM marketing, advertising, and consulting services, and retail of pharmaceuticals and decoction products. These diverse activities enable the company to serve hospitals and retail pharmacies effectively. Formerly known as China Traditional Chinese Medicine Co. Limited, the company adopted its current name in July 2016, reflecting its evolution and expanded scope of operations. The company also provides property leasing services.
Was das Unternehmen tut
- Researches and develops traditional Chinese medicine (TCM) products.
- Produces a range of TCM products, including granules, finished drugs, and decoction pieces.
- Sells its TCM products to hospitals and retail pharmacies.
- Cultivates and manages Chinese medicinal herbs.
- Trades pharmaceutical products.
- Provides TCM marketing, advertising, and consulting services.
- Engages in the retail of pharmaceuticals and decoction products.
- Provides property leasing services.
Geschaeftsmodell
- Develops and manufactures TCM products.
- Generates revenue through the sale of TCM products to hospitals and retail pharmacies.
- Supplements revenue through trading of pharmaceutical products and provision of TCM-related services.
- Derives income from property leasing activities.
Branchenkontext
China Traditional Chinese Medicine Holdings Co. Limited operates within the growing Chinese pharmaceutical market, specifically focusing on traditional Chinese medicine. The TCM market is driven by increasing consumer awareness of natural remedies and government support for the industry. However, the industry faces challenges such as stringent regulations, quality control issues, and competition from both domestic and international players. The company's established presence and integrated operations provide a competitive advantage, but it must navigate these challenges to maintain its market position.
Wichtige Kunden
- Hospitals throughout China.
- Retail pharmacies across China.
- Patients seeking TCM treatments.
- Other pharmaceutical companies (through trading activities).
Finanzdaten
Chart & Info
China Traditional Chinese Medicine Holdings Co. Limited (CHIZF) Aktienkurs: Price data unavailable
Aktuelle Nachrichten
Keine aktuellen Nachrichten fuer CHIZF verfuegbar.
Analystenkonsens
Konsens-Bewertung
Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer CHIZF.
Kursziele
Wall-Street-Kurszielanalyse fuer CHIZF.
MoonshotScore
Was bedeutet diese Bewertung?
Der MoonshotScore bewertet das Wachstumspotenzial von CHIZF auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.
Fuehrung: Jun Yang
Unknown
Information on Jun Yang's background is not available in the provided data. Details regarding his career history, education, and previous roles are unknown. Further research would be needed to provide a comprehensive profile.
Erfolgsbilanz: Information on Jun Yang's track record is not available in the provided data. Specific achievements, strategic decisions, and company milestones under his leadership are unknown. Further research would be needed to provide a detailed assessment.
CHIZF OTC-Marktinformationen
The OTC Other tier represents the lowest tier of the OTC market, indicating that China Traditional Chinese Medicine Holdings Co. Limited may not meet the minimum financial or disclosure requirements of higher tiers like OTCQX or OTCQB, or major exchanges like NYSE or NASDAQ. Companies in this tier often have limited operating history, are thinly traded, and may not be subject to stringent regulatory oversight. This contrasts with listed exchanges, which have specific listing standards and reporting requirements designed to protect investors.
- OTC-Stufe: OTC Other
- Offenlegungsstatus: Unknown
- Limited Disclosure: OTC companies often have less stringent disclosure requirements, making it difficult to assess their financial health and operational performance.
- Low Liquidity: OTC stocks can be thinly traded, leading to wide bid-ask spreads and difficulty in buying or selling shares.
- Regulatory Oversight: OTC markets are subject to less regulatory oversight than major exchanges, increasing the risk of fraud and manipulation.
- Price Volatility: OTC stocks can be more volatile than those listed on major exchanges due to lower trading volumes and less institutional interest.
- Information Asymmetry: Limited access to information can create an uneven playing field for investors.
- Verify the company's registration and regulatory filings.
- Review the company's financial statements, if available.
- Assess the company's business model and competitive landscape.
- Evaluate the company's management team and corporate governance.
- Check for any legal or regulatory issues.
- Monitor trading activity and liquidity.
- Consult with a financial advisor.
- Long operating history (founded in 1573).
- Presence in the Chinese market.
- Number of employees (16753).
- Tangible business operations (research, development, production, and sale of TCM products).
- Involvement in the cultivation of Chinese medicinal herbs.
Haeufige Fragen zu CHIZF
What are the key factors to evaluate for CHIZF?
China Traditional Chinese Medicine Holdings Co. Limited (CHIZF) currently holds an AI score of 44/100, indicating low score. Key strength: Long-standing history and established brand in the TCM market.. Primary risk to monitor: Potential: Stringent regulations and quality control requirements in the pharmaceutical industry.. This is not financial advice.
How frequently does CHIZF data refresh on this page?
CHIZF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven CHIZF's recent stock price performance?
Recent price movement in China Traditional Chinese Medicine Holdings Co. Limited (CHIZF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Long-standing history and established brand in the TCM market.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider CHIZF overvalued or undervalued right now?
Determining whether China Traditional Chinese Medicine Holdings Co. Limited (CHIZF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying CHIZF?
Before investing in China Traditional Chinese Medicine Holdings Co. Limited (CHIZF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding CHIZF to a portfolio?
Potential reasons to consider China Traditional Chinese Medicine Holdings Co. Limited (CHIZF) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Long-standing history and established brand in the TCM market.. Additionally: Integrated operations, from herb cultivation to product distribution.. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.
Can I buy fractional shares of CHIZF?
Yes, most major brokerages offer fractional shares of China Traditional Chinese Medicine Holdings Co. Limited (CHIZF) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track CHIZF's earnings and financial reports?
China Traditional Chinese Medicine Holdings Co. Limited (CHIZF) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for CHIZF earnings announcements is recommended.
Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.
Offizielle Ressourcen
Daten dienen ausschliesslich zu Informationszwecken.
- Information is based on available data and may be subject to change.
- AI analysis is pending and may provide additional insights in the future.
- OTC market data may be limited and less reliable than data for listed exchanges.